NEO icon

NeoGenomics

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 85.7%
Negative

Neutral
Seeking Alpha
yesterday
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral
Business Wire
3 days ago
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer.
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
Neutral
Business Wire
10 days ago
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neutral
Business Wire
16 days ago
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
Neutral
Business Wire
1 month ago
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
Neutral
Business Wire
1 month ago
NeoGenomics to Present New ctDNA Research at SABCS 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
NeoGenomics to Present New ctDNA Research at SABCS 2025
Neutral
Business Wire
1 month ago
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
Neutral
Seeking Alpha
2 months ago
Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript
Neo Performance Materials Inc. ( NEO:CA ) Q3 2025 Earnings Call November 14, 2025 10:00 AM EST Company Participants Karen Murray Rahim Suleman - CEO, President & Director Jonathan Baksh - Executive VP & CFO Conference Call Participants Daniel Harriman - Sidoti & Company, LLC Nicholas Boychuk - Cormark Securities Inc., Research Division Ian Gillies - Stifel Nicolaus Canada Inc., Research Division Presentation Operator Good morning, and welcome to the Neo Performance Materials Third Quarter 2025 Earnings Conference Call. For opening remarks and introduction, let me turn the call over to Karen Murray, General Counsel for Neo.
Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript
Neutral
Business Wire
2 months ago
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 37th Annual Healthcare Conference.
NeoGenomics to Participate in Upcoming Investor Conferences
Neutral
Business Wire
2 months ago
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors